Introduction
Among the various biomedical imaging modalities, magnetic resonance imaging (MRI) -which provides high-resolution anatomical images in a noninvasive manner -is one of the most powerful tools. 1, 2 In 40%-50% cases of clinical application, magnetic resonance (MR) contrast agents (CAs) are introduced to enhance the contrast, presenting improved sensitivity and quality of the images for more accurate diagnosis. 3 MRI CAs, generally in the form of T 1 -positive and T 2 -negative CAs, greatly improve the sensitivity of MRI by affecting the rate of water proton relaxation. For T 1 -weighted CAs, paramagnetic 4608 li et al complexes containing gadolinium (Gd 3+ ) and manganese (Mn 2+ ) ions are commonly used to effectively accelerate the T 1 relaxation process to produce a brighter image. [4] [5] [6] [7] [8] [9] In contrast, T 2 -weighted CAs, such as the superparamagnetic iron oxide nanoparticles (SPIOs), exhibit strong magnetization when an external magnetic field is applied. This causes microscopic field inhomogeneity and activates the dephasing of protons to produce decreased signal intensity in T 2 -and T 2 *-weighted MR images. 10, 11 However, each modal CA has its own unique advantages and limitations. For example, the commonly used T 1 CAs are relatively small molecules, which are fast excreted by the kidneys, thereby resulting in difficulty with high-resolution image acquisition. Moreover, the functionalization of paramagnetic complexes with targeting molecules is hampered by the arduous and complex modification process. [12] [13] [14] On the other hand, SPIOs as T 2 MR CAs are very useful for biomedical applications because they are not subject to strong magnetic interactions in dispersion and are readily stabilized under physiological conditions. 15 However, the biggest issue with using T 2 CAs is that it is difficult to distinguish the signal from an air bubble or image artifact. Due to the negative contrast effect and susceptibility artifacts, it is difficult to distinguish the region of signals induced by SPIOs from low-level background MR signals, such as signals arising from adjacent tissues, bone, or vasculature. 11 Furthermore, independent T 1 or T 2 MR imaging suffers from false-positive signals that are ubiquitously observed in tissues. Last but not the least, T 1 -T 2 dual imaging displays obvious advantages over single imaging with regard to water and fat molecules in tissue. For example, some tissue components such as the bone and fiber components present low signals on T 1 WI similar to water. Moreover, some tissue components such as bleeding and mucus present high signals on the T 1 WI similar to fat. It is difficult to distinguish water and fat with single imaging. However, with T 1 -T 2 dual imaging, these issues can be addressed. Water presents a low signal on T 1 WI and a high signal on T 2 WI. Fat presents a high signal on both T 1 WI and T 2 WI. Thus, it is easy to recognize water and fat with dual imaging. Therefore, the development of T 1 -T 2 dual CAs is emerging attractively because they have the ability to validate reconstruction and visualization of the data in a more accurate and reliable manner, and to acquire complementary and self-confirmed information to permit meaningful interpretation. 16 Several kinds of dual CAs have been reported to improve the diagnostic accuracy of diseases. [17] [18] [19] [20] [21] [22] [23] [24] Choi et al developed a nanoparticle (NP)-based dual CA -MnFe 2 O 4 @ SiO 2 @Gd 2 O(CO 3 ) 2 -which not only possessed superior MR contrast effects, but also had the unique capability of displaying "AND" logic signals in both T 1 and T 2 modes. 22 Bae et al synthesized Gd-labeled Fe 3 O 4 NPs and demonstrated their capability as dual CAs for T 1 -and T 2 -weighted MRI. 21 For the design of T 1 -T 2 dual CAs, two main aspects should be concerned. Firstly, to obtain high sensitivity, the T 1 and T 2 CAs themselves should possess good MRI relaxivities. High relaxivity is the primary requisite for the development of molecular imaging MR probes and targeting probes. [25] [26] [27] Several strategies for increasing the sensitivity (relaxivity) of MRI CAs have been well reviewed. [28] [29] [30] Secondly, the undesirable T 1 signal quenching of the paramagnetic T 1 CA by the magnetic field generated by a superparamagnetic T 2 CA when they are in proximity should be avoided. To address these issues, in this study, we aimed to synthesize the Fe 3 O 4 @mSiO 2 /PDDA/BSA-Gd 2 O 3 nanocomplex (Scheme 1) and explore its potential as a T 1 -T 2 dual CA to obtain better MRI contrast enhancement and specific tumor cell targeting. BSA-Gd 2 O 3 NPs and Fe 3 O 4 NPs were chosen as T 1 and T 2 MRI CAs. High-Gd density paramagnetic ultrasmall gadolinium oxide nanoparticles (Gd 2 O 3 NPs) have emerged to present larger T 1 relaxivity, good biocompatibility, and easy conjugation with other biomolecules or imaging agents for molecular MRI (mMRI) and multimodal molecular imaging. 18 
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T 1 -T 2 molecular MrI based on nano-contrast agents the magnetic spin interactions between T 1 and T 2 CAs. It has been proved that the magnetic field generated by a superparamagnetic T 2 CA could perturb the electronic spins of paramagnetic T 1 CA when they are in close proximity (,12 nm). 22 Furthermore, to realize the specific tumor cell imaging, an AS1411 aptamer, which can selectively bind with nucleolin overexpressed on a variety of cancer cells, was employed as the tar geting molecule for the fabrication of the mMRI nanoprobeFe 3 O 4 @mSiO 2 /PDDA/BSA-Gd 2 O 3 -AS1411. [33] [34] [35] Its ability for the specific targeting of renal cell carcinoma (RCC) was confirmed by the T 1 -T 2 -weighted MRI.
Materials and methods

Materials and reagents
Bovine serum albumin (BSA) was obtained from Solarbio (Beijing, People's Republic of China). Gd(NO 3 ) 3 ⋅6H 2 O, hexadecyl trimethyl ammonium bromide (CTAB), and dimethyl sulfoxide (DMSO) were purchased from Sinopharm Chemical Reagent Co. Ltd., Beijing, People's Republic of China Tetraethylorthosilicate (TEOS), poly(dimethyl diallyl ammonium chloride) (PDDA), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC⋅HCl), and N-hydroxysuccinimide (NHS) were purchased from Sigma-Aldrich (Saint Louis, MO, USA). DNA oligos were synthesized and purified by Shanghai Sangon Biotechnology Co. Ltd. (Shanghai, People's Republic of China); 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was obtained from Sunshine Biotech. Co. Ltd. (Nanjing, People's Republic of China). Cell culture media including HDMEM, RPMI 1640, and fetal calf serum were obtained from Kangmei Biotechnology Co. Ltd (Xuzhou, People's Republic of China). All other reagents were of analytical grade and used without purification. All aqueous solutions were prepared using ultrapure water from a Milli-Q system (Millipore, Boston, MA, USA). The DNA sequence is listed as follows.
COOH-AS1411: 5 ′ -COOH-GGTGGTGGTGGTTGTGGTGGTG GTGG-3′.
apparatus and characterization
The size and morphology of NPs were observed by transmission electron microscopy (TEM; TECNAI G2, FEI Company, Hillsboro, OR, USA). Fourier transform infrared absorption (FTIR) spectra were obtained through FTIR spectroscopy (Bruker, Billerica, MA, USA). Zeta potentials were determined by Nano ZS90 (Malvern Panalytical Ltd, Malvern, England). X-ray powder diffraction (XRD) patterns were obtained by using a X-ray powder diffractometer (D8 ADVANCE, Bruker). The determinations of Gd and iron ion concentrations were undertaken with inductively coupled plasma-mass spectrometry (ICP-MS) (Optima 5300DV, PerkinElmer, San Diego, CA, USA). The absorbances for MTT assay were determined by a microplate reader (Multiskan MK3, Thermo Fisher Scientific, Waltham, MA, USA) at 490 nm. MRI scanning was conducted on a Signa HDxt 3.0T, General Electric Company, Boston, Massachusetts, USA. Hematologic and biochemical analysis was carried out with a hematology analyzer (Mindray BC-5390, Mindray Bio-Medical Electronics Co., Ltd., Shenzhen, People's Republic of China) and cobas connection modules (Roche Diagnostics, Basel, Switzerland), respectively.
cells and cell culture conditions
The 786-0 renal carcinoma cells and NIH-3T3 mouse fibroblast cells were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, People's Republic of China). The 786-0 renal carcinoma cells were cultured in a 10% FBScontaining RPMI 1640 medium (Sijiqing, People's Republic of China) supplemented with penicillin (100 mg/mL) and streptomycin (100 mg/mL). NIH-3T3 cells were propagated in 10% FBS-containing Dulbecco's Modified Eagle's Medium (Gibco, Grand Island, NY, USA) supplemented with penicillin (100 mg/mL) and streptomycin (100 mg/mL). All cells were grown in a humidified incubator (Thermo Fisher Scientific) at 37°C under 5% CO 2 atmosphere.
Preparation of Fe 3 O 4 NPs
The Fe 3 O 4 NPs were synthesized using a previously reported method. 36 In brief, approximately 10 mL water containing 1.0 mol/L Fe 3+ and 0.5 mol/L Fe 2+ ions (molar ratio 2:1) was stirred at 400 rpm on a stir plate for 20 min. Then, 30 mL ammonium hydroxide was slowly added to the solution and the speed was increased to 900 rpm in order to uniformly precipitate magnetic NPs. In a typical procedure, 37 CTAB (50 mg) was dissolved in 20.8 mL distilled water. In total, 4.2 mL Fe 3 O 4 and NaOH solution (2.00 M, 160 µL) were added to the above CTAB solution sequentially. Then, the mixture was heated to 70°C with stirring, and 250 µL TEOS and 500 µL ethylacetate were added to the reaction solution in sequence. The mixture was stirred for 3 h at 70°C. The resultant precipitate was washed 3 times with ethanol to remove the unreacted species and then dispersed in 20 mL ethanol. To extract CTAB, 20 µL HCl was added to the dispersion mixture (pH.1.0) and stirred for 3 h 4610 li et al at 60°C. To obtain hollow mesoporous silica, more HCl was used for extraction (pH ,1.0). After washing three times with ethanol, the Fe 3 O 4 @mSiO 2 NPs were dried at 50°C.
Preparation of Bsa-gd 2 O 3 NPs
BSA-Gd 2 O 3 NPs were synthesized according to the methods specified in the literature with some modifications. 38 In total, 0.25 g BSA was dissolved in 9 mL distilled water. Then, 1 mL 50 mM Gd(NO 3 ) 3 was added to the above solution slowly under vigorous stirring. After the introduction of 1 mL 2 M NaOH 5 min later, the mixture was allowed to react under vigorous stirring at 37°C for 12 h. Finally, the BSA-Gd 2 O 3 thus prepared was dialyzed against distilled water (1:1,000, v/v) to remove excess precursors. 40 Briefly, 100 µM COOH-AS1411 (50 µL) was mixed with EDC (100 µL, 10 mg mL -1 ) in 300 µL PBS (10 mM, pH 7.4) and incubated at 37°C for 15 min to form an active carboxyl group. Then, NHS (100 µL, 10 mg mL ) were added to the mixture and reacted at 37°C for 2 h. The unreacted biomolecules were removed by two centrifugation/washing cycles. Finally, the ). After 24-h incubation, the medium was removed, and fresh medium (100 µL) containing MTT (20 µL, 5 mg mL
Fabrication of
MTT assay
) was added into each well. Four hours later, the culture medium was carefully removed and washed, and 100 mL DMSO was added to each well to dissolve the formazan crystals for 10 min. The absorbance at 490 nm was measured by a microplate reader (Multiskon MK3, USA).
stability test
The ) were added into the well and incubated for 1 h at 37°C. After discarding the nanoprobe, the cells were washed and lysed by trypsin. The harvested cells were fixed with 600 µL 1% agarose for MRI scanning. The untreated cells that were incubated with PBS were taken as the control.
Biodistribution of the Fe 3 O 4 @msiO 2 / PDDa/Bsa-gd 2 
O 3 nanocomplex in the mouse
The residual nanocomplex in heart, liver, kidneys, and lungs after 1 h and 24 h post-injection of the Fe 3 O 4 @mSiO 2 /PDDA/ BSA-Gd 2 O 3 nanocomplex was determined by the quantification of the Gd element by ICP-MS. Briefly, six Kunming mice were divided into two groups: 1-h post-injection and 24-h postinjection. Each mouse was injected with the same concentration of the Fe 3 O 4 @mSiO 2 /PDDA/BSA-Gd 2 O 3 nanocomplex (0.16 mmol Gd per kg body weight). The mice were sacrificed and the major organs, including heart, liver, kidneys, and lungs, were collected at 1 h and 24 h post-injection. To these organs, 2 mL aqua regia (HCl:HNO 3 =3:1) was added and the organs in aqua regia were heated to 200°C for 1 h. After being cooled to room temperature, 2 mL H 2 O was added and a 0.22-µm filter was introduced to remove undigested tissues. 41 The Gd concentrations were then analyzed by ICP-MS. 
In vivo toxicity evaluation of
In vivo MrI
Animal experiments were conducted in accordance with the National Institutes of Health guidelines on the use of animals in research, and were approved by the Animal Care Committee of Xuzhou Medical University. Healthy BALB/c mice weighing 20-30 g were chosen for in vivo MRI study. The mice were anesthetized by intraperitoneal injection of 2% mebumalnatrium (4 µL/g bodyweight), followed by tail-vein administration of the Fe 3 O 4 @mSiO 2 / PDDA/BSA-Gd 2 O 3 nanocomplex (0.16 mmol Gd per kg body weight). Then, at scheduled intervals, T 1 WI images and T 2 WI images were acquired by a 3.0 T MR imaging system (GE Discovery 750W, USA) with the animal T/R coil (Magtron Inc., Jiangyin, People's Republic of China). The sequences for T 1 -weighted images were set as follows: TE=12 ms; TR=400 ms; FOV=80×80 mm; slice thickness=2 mm; spacing=0.2 mm; and matrix=256×256. The sequences for T 2 -weighted images were set as follows: TE=58 ms; TR=300 ms; FOV=80×48 mm; slice thickness=2 mm; spacing=0.2 mm; and matrix=256×256. To compare the signal intensity at different time points, the same protocols, prone position, and the same scanning landmark of MRI were required. The relative intensity changes of the same region of interest on the same slice in the same window width and window level were recorded by software in the workstation GE AW4.6. Then, the further conjugation of the AS1411 aptamer with the Fe 3 O 4 @mSiO 2 /PDDA/BSA-Gd 2 O 3 nanocomplex through a covalent coupling reaction was confirmed by the FTIR absorption spectrum and UV-vis absorption spectrum. The emerging absorption peak at 1,630 and 1,652 cm -1 was ascribed to acylamide vibration in the FTIR absorption spectrum ( Figure 1C) , and a characteristic UV-vis absorbance peak of the AS1411 aptamer could be observed in the Fe 3 O 4 @mSiO 2 /PDDA/ BSA-Gd 2 O 3 -AS1411 nanoprobe ( Figure 1D ), both indicating the successful preparation of the mMRI nanoprobe. Figure S4 and Figure 5 ). 43, 44 Such excellent MR imaging behavior indicated the ability of the Fe 3 O 4 @mSiO 2 /PDDA/BSA-Gd 2 O 3 nanocomplex (the molar value of Fe/Gd equals 0.539; r 1 /r 2 equals 0.0567) as a promising T 1 -T 2 dual MRI CA for the fabrication of an mMRI nanoprobe to specifically image tumor cells. 
Results
when the BSA-Gd 2 O 3 NP concentration was 1.06 µM Gd, the T
In vitro cytotoxicity test
Before the use of the Fe 3 O 4 @mSiO 2 /PDDA/BSA-Gd 2 O 3 nanocomplex for specific tumor cell imaging, it is vital to assess its safety in vitro. The MTT assay was conducted to evaluate the cell toxicity of the nanocomplex and identify potentially safe concentrations for the following targeting experiments. The Fe 3 O 4 @mSiO 2 /PDDA/BSA-Gd 2 O 3 nanocomplex with eight different concentrations, ranging from 0 to 1,400 µg/mL, was incubated with 786-0 and NIH-3T3 cells for 24 h, respectively. As shown in Figure 6 , the Fe 3 O 4 @ mSiO 2 /PDDA/BSA-Gd 2 O 3 nanocomplex displayed good biocompatibility, and no significant cytotoxicity was observed both on 786-0 renal carcinoma or NIH-3T3 cells.
stability test
The leaching of metallic ions is a potential harmful effect of their biological application. To test the possibility of Gd and Fe ions leaching from the nanocomplex in biological media, we determined the concentrations of Gd and Fe ions in the supernatant with the passage of time from when the nanocomplex was dispersed in the cell culture medium and in different pH solutions incubated for 24 h. As shown in Figure 7 , no obvious Gd and Fe ion leaching could be observed with time in the cell culture medium or different pH solutions, indicating the good stability of our fabricated nanocomplex.
In vitro specific T 1 -T 2 dual Mr imaging of tumor cells
Finally, the specific cellular targeting of the Fe 3 O 4 @mSiO 2 / PDDA/BSA-Gd 2 O 3 -AS1411 mMRI nanoprobe was evaluated by T 1 -T 2 MRI. AS1411 is a nucleolus of specific nucleic acid aptamers, which can specifically combine with nucleolin Figure 10 , the Gd concentration in the above organs all decreased, except in the kidney. The residual Gd concentrations in heart, liver, kidneys, and lungs were 1.90±0.12, 2.41±0.06, 2.15±0.08, and 2.27±0.1 µg/g at 1 h post-injection and 1.54±0.11, 1.94±0.12, 2.46±0.14, and 1.69±0.17 µg/g at 24 h post-injection, respectively.
In vivo toxicity evaluation
The in vivo toxicity of the Fe 3 O 4 @mSiO 2 /PDDA/BSA-Gd 2 O 3 nanocomplex was evaluated with standard hematologic and biochemical analyses and by referring to the literature. 45 Compared with the normal saline group, the HCT, HGB, RBC, WBC, MCV, MCH, and MCHC levels in the Fe 3 O 4 @ mSiO 2 /PDDA/BSA-Gd 2 O 3 nanocomplex group showed no statistically significant differences, except for PLT ( Figure 11 ). The ALT, AST, BUN, CREA, TP, ALB, and TBIL levels displayed no statistically significant difference between the normal saline group and the Fe 3 O 4 @mSiO 2 / PDDA/BSA-Gd 2 O 3 nanocomplex group (Figure 12 ). Notes: *Refers to statistically significant differences compared with the control group using one-way ANOVA (p,0.05).
#
Refers to statistically significant differences compared with the control group with one-way aNOVa (p,0.05). a Refers to statistically significant differences within group with LSD Duncan (p,0.05).
b refers to statistically significant differences within group with LSD Duncan (p,0.05). 
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T 1 -T 2 molecular MrI based on nano-contrast agents
In vivo MrI
For in vivo MR imaging, T 1 and T 2 dual-mode images were obtained pre-and post-injection of the Fe 3 O 4 @mSiO 2 / PDDA/BSA-Gd 2 O 3 nanocomplex using a 3T MR scanner at room temperature. MRI images were collected at scheduled intervals of 24 h post-injection. As shown in Figures 13 and S7 , compared with the pre-injection reference, a darker signal in T 2 -weighted images and a brighter signal in T 1 -weighted images in the kidney at 15 min after administration were observed. However, at the 6-h time point, such signal contrasts in the kidney brought by the nanocomplex injection became weaker and the signal contrasts in the bladder became stronger, indicating that the excretion of the nanocomplex was mainly via the kidneys and bladder. These results showed the potential of the Fe 3 O 4 @mSiO 2 /PDDA/BSA-Gd 2 O 3 nanocomplex as an effective T 1 -T 2 dual-mode CA for in vivo MRI with self-confirmation. ). As reported, in a certain range, the larger the size of NPs, the stronger the saturation magnetization and relaxation rate of the nanomaterials. 46 In our work, the existence of PDDA favored more BSA-Gd 2 
Discussion
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T 1 -T 2 molecular MrI based on nano-contrast agents function, which might result in severe clinical outcomes. 47 For example, Radomski et al found multi-or single-walled carbon nanotubes (MWCNTs or SWCNTs) induced PLT activation and aggregation whereas C60 fullerences (nC60) had no effect. 48 Reinish et al observed a reduction in the PLT blood count in the first 5 min after the injection of negatively charged liposomes to rats, but noted a recovery of PLT count after 60 min post-injection. 49 Nanomaterial properties such as size, shape, chemical composition, and surface physicochemical property influence their effect on PLT, obviously. For biochemical analysis, the commonly used serum biochemical parameters including AST, ALT, TP, ALB, TBL, BUN, and CREA were measured. ALT and AST are commonly used indicators of liver function. Creatinine and BUN are important indicators of kidney function. 45 Compared with the normal saline-treated group, no statistically significant difference was observed in the above parameters in the The biodistribution and clearance of nanomaterials in vivo is related to the characteristics of nanomaterials and organ specificity, such as hydrodynamic size, the surface charge, surface modification, and so on. [50] [51] [52] It was reported that NPs with a hydrodynamic diameter less than 5.5 nm could be excreted by renal clearance, and those with a hydrodynamic diameter more than 15 nm were usually captured and eliminated through the liver into bile and into feces. 53, 54 However, in our case, the increase of Gd concentration in the kidney with time indicated the possible excretion route of the Fe 3 O 4 @mSiO 2 /PDDA/BSA-Gd 2 O 3 nanocomplex from the body through the kidneys, as even its hydrodynamic size was approximately 345.6 nm. This result was similar with that reported in Mekuria et al's report; they prepared G4.5-Gd 2 O 3 -PEG NPs with a hydrodynamic diameter of approximately 50 nm. They concluded that the kidneys removed NPs from the vascular compartment to the gall bladder. 55 This means the clearance route of nanomaterials was not only related to the hydrodynamic size, but also to other factors. The Gd concentrations in the heart, liver, and lung all decreased with time, as indicated by the gradual clearance of the Fe 3 O 4 @mSiO 2 /PDDA/BSA-Gd 2 O 3 nanocomplex from the body.
Conclusion
The introduction of CAs has improved the sensitivity of MRI greatly, stimulating its wider application in disease diagnosis. However, single-mode CAs are not yet perfected. Notes: *Refers to statistically significant differences when compared with the other two groups using one-way ANOVA (p,0.05).
#
Refers to statistically significant differences when compared with the other two groups using one-way aNOVa (p,0.05). Notes: *Refers to statistically significant differences when compared with control group using one-way ANOVA (p,0.05).
Refers to statistically significant differences when compared with the control group using one-way aNOVa (p,0.05). a Refers to statistically significant differences between NIH-3T3 and 786-0 cells with LSD Duncan (p,0.05).
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